Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Plasma Protease C1-inhibitor Treatment market report explains the definition, types, applications, major countries, and major players of the Plasma Protease C1-inhibitor Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Shire plc
Pharming Group NV
Sanquin
CSL Limited
By Type:
By Drug Class
C1-inhibitors
Kallikrein Inhibitor (Kalbitor)
Selective Bradykinin B2 Receptor Antagonist (Firazyr)
By Dosage Type
Liquid/Injectable
Lyophilized
By End-User:
Hospital Pharmacies
Independent Pharmacies and Outlets
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Plasma Protease C1-inhibitor Treatment Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Plasma Protease C1-inhibitor Treatment Outlook to 2028- Original Forecasts
-
2.2 Plasma Protease C1-inhibitor Treatment Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Plasma Protease C1-inhibitor Treatment Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Plasma Protease C1-inhibitor Treatment Market- Recent Developments
-
6.1 Plasma Protease C1-inhibitor Treatment Market News and Developments
-
6.2 Plasma Protease C1-inhibitor Treatment Market Deals Landscape
7 Plasma Protease C1-inhibitor Treatment Raw Materials and Cost Structure Analysis
-
7.1 Plasma Protease C1-inhibitor Treatment Key Raw Materials
-
7.2 Plasma Protease C1-inhibitor Treatment Price Trend of Key Raw Materials
-
7.3 Plasma Protease C1-inhibitor Treatment Key Suppliers of Raw Materials
-
7.4 Plasma Protease C1-inhibitor Treatment Market Concentration Rate of Raw Materials
-
7.5 Plasma Protease C1-inhibitor Treatment Cost Structure Analysis
-
7.5.1 Plasma Protease C1-inhibitor Treatment Raw Materials Analysis
-
7.5.2 Plasma Protease C1-inhibitor Treatment Labor Cost Analysis
-
7.5.3 Plasma Protease C1-inhibitor Treatment Manufacturing Expenses Analysis
8 Global Plasma Protease C1-inhibitor Treatment Import and Export Analysis (Top 10 Countries)
-
8.1 Global Plasma Protease C1-inhibitor Treatment Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Plasma Protease C1-inhibitor Treatment Export by Region (Top 10 Countries) (2017-2028)
9 Global Plasma Protease C1-inhibitor Treatment Market Outlook by Types and Applications to 2022
-
9.1 Global Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global By Drug Class Consumption and Growth Rate (2017-2022)
-
9.1.2 Global C1-inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Kallikrein Inhibitor (Kalbitor) Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Selective Bradykinin B2 Receptor Antagonist (Firazyr) Consumption and Growth Rate (2017-2022)
-
9.1.5 Global By Dosage Type Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Liquid/Injectable Consumption and Growth Rate (2017-2022)
-
9.1.7 Global Lyophilized Consumption and Growth Rate (2017-2022)
-
9.2 Global Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Independent Pharmacies and Outlets Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Plasma Protease C1-inhibitor Treatment Market Analysis and Outlook till 2022
-
10.1 Global Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.2.2 Canada Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.2.3 Mexico Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.2 UK Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.3 Spain Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.4 Belgium Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.5 France Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.6 Italy Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.7 Denmark Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.8 Finland Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.9 Norway Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.10 Sweden Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.11 Poland Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.12 Russia Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.3.13 Turkey Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4.2 Japan Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4.3 India Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4.4 South Korea Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4.5 Pakistan Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4.6 Bangladesh Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4.7 Indonesia Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4.8 Thailand Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4.9 Singapore Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4.10 Malaysia Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4.11 Philippines Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.4.12 Vietnam Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.5.2 Colombia Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.5.3 Chile Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.5.4 Argentina Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.5.5 Venezuela Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.5.6 Peru Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.5.7 Puerto Rico Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.5.8 Ecuador Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.6.2 Kuwait Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.6.3 Oman Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.6.4 Qatar Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.6.5 Saudi Arabia Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.6.6 United Arab Emirates Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.7.2 South Africa Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.7.3 Egypt Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.7.4 Algeria Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
10.8.2 New Zealand Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
11 Global Plasma Protease C1-inhibitor Treatment Competitive Analysis
-
11.1 Shire plc
-
11.1.1 Shire plc Company Details
-
11.1.2 Shire plc Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Shire plc Plasma Protease C1-inhibitor Treatment Main Business and Markets Served
-
11.1.4 Shire plc Plasma Protease C1-inhibitor Treatment Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Pharming Group NV
-
11.2.1 Pharming Group NV Company Details
-
11.2.2 Pharming Group NV Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Pharming Group NV Plasma Protease C1-inhibitor Treatment Main Business and Markets Served
-
11.2.4 Pharming Group NV Plasma Protease C1-inhibitor Treatment Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Sanquin
-
11.3.1 Sanquin Company Details
-
11.3.2 Sanquin Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Sanquin Plasma Protease C1-inhibitor Treatment Main Business and Markets Served
-
11.3.4 Sanquin Plasma Protease C1-inhibitor Treatment Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 CSL Limited
-
11.4.1 CSL Limited Company Details
-
11.4.2 CSL Limited Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 CSL Limited Plasma Protease C1-inhibitor Treatment Main Business and Markets Served
-
11.4.4 CSL Limited Plasma Protease C1-inhibitor Treatment Product Portfolio
-
11.4.5 Recent Research and Development Strategies
12 Global Plasma Protease C1-inhibitor Treatment Market Outlook by Types and Applications to 2028
-
12.1 Global Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global By Drug Class Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global C1-inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Kallikrein Inhibitor (Kalbitor) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Selective Bradykinin B2 Receptor Antagonist (Firazyr) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global By Dosage Type Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Liquid/Injectable Consumption Forecast and Growth Rate (2022-2028)
-
12.1.7 Global Lyophilized Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Independent Pharmacies and Outlets Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Plasma Protease C1-inhibitor Treatment Market Analysis and Outlook to 2028
-
13.1 Global Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.2.2 Canada Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.2.3 Mexico Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.2 UK Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.3 Spain Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.4 Belgium Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.5 France Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.6 Italy Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.7 Denmark Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.8 Finland Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.9 Norway Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.10 Sweden Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.11 Poland Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.12 Russia Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.3.13 Turkey Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4.2 Japan Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4.3 India Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4.4 South Korea Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4.8 Thailand Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4.9 Singapore Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4.11 Philippines Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.5.2 Colombia Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.5.3 Chile Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.5.4 Argentina Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.5.6 Peru Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.6.3 Oman Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.6.4 Qatar Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.7.2 South Africa Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.7.3 Egypt Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.7.4 Algeria Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Plasma Protease C1-inhibitor Treatment
-
Figure of Plasma Protease C1-inhibitor Treatment Picture
-
Table Global Plasma Protease C1-inhibitor Treatment Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Plasma Protease C1-inhibitor Treatment Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global By Drug Class Consumption and Growth Rate (2017-2022)
-
Figure Global C1-inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Kallikrein Inhibitor (Kalbitor) Consumption and Growth Rate (2017-2022)
-
Figure Global Selective Bradykinin B2 Receptor Antagonist (Firazyr) Consumption and Growth Rate (2017-2022)
-
Figure Global By Dosage Type Consumption and Growth Rate (2017-2022)
-
Figure Global Liquid/Injectable Consumption and Growth Rate (2017-2022)
-
Figure Global Lyophilized Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Independent Pharmacies and Outlets Consumption and Growth Rate (2017-2022)
-
Figure Global Plasma Protease C1-inhibitor Treatment Consumption by Country (2017-2022)
-
Table North America Plasma Protease C1-inhibitor Treatment Consumption by Country (2017-2022)
-
Figure United States Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Canada Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Mexico Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Table Europe Plasma Protease C1-inhibitor Treatment Consumption by Country (2017-2022)
-
Figure Germany Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure UK Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Spain Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Belgium Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure France Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Italy Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Denmark Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Finland Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Norway Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Sweden Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Poland Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Russia Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Turkey Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Table APAC Plasma Protease C1-inhibitor Treatment Consumption by Country (2017-2022)
-
Figure China Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Japan Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure India Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure South Korea Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Thailand Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Singapore Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Philippines Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Table South America Plasma Protease C1-inhibitor Treatment Consumption by Country (2017-2022)
-
Figure Brazil Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Colombia Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Chile Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Argentina Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Peru Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Table GCC Plasma Protease C1-inhibitor Treatment Consumption by Country (2017-2022)
-
Figure Bahrain Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Oman Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Qatar Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Table Africa Plasma Protease C1-inhibitor Treatment Consumption by Country (2017-2022)
-
Figure Nigeria Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure South Africa Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Egypt Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Algeria Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Table Oceania Plasma Protease C1-inhibitor Treatment Consumption by Country (2017-2022)
-
Figure Australia Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Table Shire plc Company Details
-
Table Shire plc Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shire plc Plasma Protease C1-inhibitor Treatment Main Business and Markets Served
-
Table Shire plc Plasma Protease C1-inhibitor Treatment Product Portfolio
-
Table Pharming Group NV Company Details
-
Table Pharming Group NV Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pharming Group NV Plasma Protease C1-inhibitor Treatment Main Business and Markets Served
-
Table Pharming Group NV Plasma Protease C1-inhibitor Treatment Product Portfolio
-
Table Sanquin Company Details
-
Table Sanquin Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanquin Plasma Protease C1-inhibitor Treatment Main Business and Markets Served
-
Table Sanquin Plasma Protease C1-inhibitor Treatment Product Portfolio
-
Table CSL Limited Company Details
-
Table CSL Limited Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table CSL Limited Plasma Protease C1-inhibitor Treatment Main Business and Markets Served
-
Table CSL Limited Plasma Protease C1-inhibitor Treatment Product Portfolio
-
Figure Global By Drug Class Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global C1-inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Kallikrein Inhibitor (Kalbitor) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Selective Bradykinin B2 Receptor Antagonist (Firazyr) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global By Dosage Type Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Liquid/Injectable Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lyophilized Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Independent Pharmacies and Outlets Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Plasma Protease C1-inhibitor Treatment Consumption Forecast by Country (2022-2028)
-
Table North America Plasma Protease C1-inhibitor Treatment Consumption Forecast by Country (2022-2028)
-
Figure United States Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Plasma Protease C1-inhibitor Treatment Consumption Forecast by Country (2022-2028)
-
Figure Germany Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Plasma Protease C1-inhibitor Treatment Consumption Forecast by Country (2022-2028)
-
Figure China Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Plasma Protease C1-inhibitor Treatment Consumption Forecast by Country (2022-2028)
-
Figure Brazil Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Plasma Protease C1-inhibitor Treatment Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Plasma Protease C1-inhibitor Treatment Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Plasma Protease C1-inhibitor Treatment Consumption Forecast by Country (2022-2028)
-
Figure Australia Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
